US-based biopharmaceutical company MediciNova plans to raise up to $200m by issuing securities on occasion.

The company plans to issue one or more offerings, including common stock, warrants, preferred stock and debt securities. It plans to use the proceeds towards general corporate purposes and other corporate expenses.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Belgian drug discovery company Confo Therapeutics has signed an agreement with Danish pharmaceutical company H. Lundbeck to use the former’s proprietary Confo technology for the discovery of novel, small molecule therapeutic compounds.

Confo Therapeutics will receive €5m ($5.94m) in research funding and is eligible to receive additional milestone payments during the first two years of collaboration.

US-based biopharmaceutical company Intra-Cellular Therapies plans to raise $150m through an underwritten public offering of common stock shares.

“US-based biopharmaceutical company Intra-Cellular Therapies plans to raise $150m through an underwritten public offering of common stock shares.”

The company plans to use the funds towards the launch and commercialisation of lumateperone.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cocrystal Pharma plans to raise $150m through a public offering of shares of its common stock, preferred stock, warrants and units.

The US-based biotechnology company plans to use the funds towards working capital and general corporate purposes.

Danish biopharmaceutical company Ascendis Pharma plans to raise $134.9m through a public offering of 3.8 million American Depositary Shares (ADSs) each priced at $35.5.

The company plans to use the funds towards the clinical development and commercialisation of its TransCon Growth Hormone.